Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.46

0.11 (0.37%)

05:38
10/19/16
10/19
05:38
10/19/16
05:38

Roche announces FDA approval of TECENTRIQ

Roche announced that the FDA approved TECENTRIQ for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumour has EGFR or ALK gene abnormalities. This approval is based on results from the randomised Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that TECENTRIQ helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy. The study enrolled people regardless of their PD-L1 status and included both squamous and non-squamous disease types.

  • 19

    Oct

  • 19

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$29.46

0.11 (0.37%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

NDX

Nasdaq 100 Index

$5,571.28

30.19686 (0.54%)

08:16
04/28/17
04/28
08:16
04/28/17
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$161.98

-2.56 (-1.56%)

08:15
04/28/17
04/28
08:15
04/28/17
08:15
Recommendations
Parker-Hannifin analyst commentary  »

Parker-Hannifin price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
U.S. Q1 GDP preview: »

U.S. Q1 GDP preview:…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

, C

Citi

$59.39

-0.55 (-0.92%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Hot Stocks
Deutsche Bank confirms James von Moltke to succeed Marcus Schenck as CFO »

Deutsche Bank's (DB)…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

C

Citi

$59.39

-0.55 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 25

    Jul

WDC

Western Digital

$85.71

1.1 (1.30%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Downgrade
Western Digital rating change  »

Western Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$918.38

9.09 (1.00%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

LH

LabCorp

$139.68

0.99 (0.71%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Hot Stocks
LabCorp to exclusively offer M3 Checklist for mental illness »

LabCorp and M-3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

ATTO

Atento

$8.85

-0.1 (-1.12%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Earnings
Atento announces prepayment of $27M Brazilian debentures »

Atento made a $26.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide an…

TER

Teradyne

$36.35

2.58 (7.64%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Teradyne analyst commentary  »

Teradyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 21

    Jun

EXPE

Expedia

$136.20

0.45 (0.33%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Expedia analyst commentary  »

Expedia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

LLL

L3 Technologies

$173.94

2.18 (1.27%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
L3 Technologies analyst commentary  »

L3 Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

, SYK

Stryker

$135.37

-0.82 (-0.60%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Downgrade
Zimmer Biomet, Stryker rating change  »

Zimmer Biomet downgraded…

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

SYK

Stryker

$135.37

-0.82 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 04

    May

PTEN

Patterson-UTI

$21.93

-1.07 (-4.65%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Recommendations
Patterson-UTI analyst commentary  »

Patterson-UTI weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

MGA

Magna

$41.40

0.56 (1.37%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Magna enters joint venture with Chinese seating supplier »

Magna has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 11

    May

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Exxon Mobil says Q1 Chemical earnings impacted primarily by lower margins »

Exxon Mobil reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

RWLK

ReWalk Robotics

$1.45

-0.2 (-12.12%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
ReWalk Robotics names Jodi Gricci as Chief Commercial Officer »

ReWalk Robotics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

HON

Honeywell

$129.88

-0.22 (-0.17%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Periodicals
Honeywell talks with Third Point still friendly, CNBC's Faber says »

Talks between Honeywell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FSS

Federal Signal

$15.38

0.98 (6.81%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
Federal Signal awarded $128K of legal costs in hearing loss litigation »

Federal Signal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.10

-0.0099 (-9.00%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Hot Stocks
CEL-SCI says European Patent office to grant new Multikine patent »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$33.05

-0.18 (-0.54%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Technical Analysis
Synchrony drops sharply after earnings miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

  • 31

    May

MSFT

Microsoft

$68.27

0.44 (0.65%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Recommendations
Microsoft analyst commentary  »

Microsoft commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.